The Administrator, AHCPR, will present the status of current Agency programs and initiatives. Tentative agenda items include the strategic directions for the Agency’s research on access, cost and use of health care services, children’s health issues, cultural competency and the implementation and evaluation of evidence based practice centers. Agenda items are subject to change as priorities dictate. The meeting will adjourn at 4:00 p.m.

John M. Eisenberg, Administrator.

[FR Doc. 98–28909 Filed 10–28–98; 8:45 am]
BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 98N–0718 and 76N–0377; DESI 7661]

Eli Lilly & Co. and Bristol-Myers Squibb Co.; Withdrawal of Approval of Three New Drug Applications for Estrogen-Androgen Combination Drugs

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of three new drug applications (NDA’s) for estrogen-androgen combination drugs. The NDA’s are held by Eli Lilly & Co. and Bristol-Myers Squibb Co. The products are no longer marketed. Both companies requested that the NDA’s be withdrawn and waived their opportunity for a hearing. The products will be removed from the list of drug products with effective approvals.


FOR FURTHER INFORMATION CONTACT: David T. Read, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: Previous Federal Register notices regarding the regulatory status of the three applications named below, as well as two others (NDA’s 10–597 and 11–267), were published on September 8, 1972 (37 FR 18225), and September 29, 1976 (41 FR 43112). (The approvals of NDA 10–597 (Tace with Androgen Capsules containing chlorotrianisone and methyltestosterone) and NDA 11–267 (Halodrin Tablets containing fluoxymesterone and ethinyl estradiol) were withdrawn in Federal Register notices of June 25, 1993 (58 FR 34466), and March 2, 1994 (59 FR 9989), respectively; see also 43 FR 49564 (October 24, 1978), which was a proposal to withdraw approval of estrogen-containing drug products labeled for use in postpartum breast engorgement.) By letter dated June 5, 1998, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543, requested that FDA withdraw approval of NDA 9–545 (Deladumone OB Injection and Deladumone Injection, each containing testosterone enanthate and estradiol valerate), stating that the marketing of Deladumone OB Injection was discontinued in 1989 when the indication for postpartum breast engorgement was withdrawn (noting that this was the only indication for Deladumone OB Injection), and that the marketing of Deladumone Injection was discontinued in 1991 because there was no longer a significant patient population requiring the concurrent therapy of an estrogen and an androgen in a fixed dose.

By letters dated July 15, 1998, and July 30, 1998, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, requested that FDA withdraw approval of NDA 7–661 (Tylosterone Tablets) and NDA 8–099 (Tylosterone Injection), both containing diethylstilbestrol and methyltestosterone, stating that the marketing of both products was discontinued in 1998 because there was no longer a significant patient population requiring the concurrent therapy of an estrogen and an androgen in a fixed dose.

Both applicants waived their opportunity for a hearing. The agency concurs in the applicants’ finding that there is not a significant patient population requiring the concurrent therapy of an estrogen and an androgen in a fixed dose.

Approval of a new drug application will be withdrawn if there is a lack of substantial evidence that the drug product covered by the application has the clinical effect that it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its labeling (21 U.S.C. 355(e)). For fixed combination prescription drugs, such substantial evidence exists only if each component makes a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy, as defined in the labeling for the drug (21 CFR 300.50). Estrogen and androgen fixed-dose combination products, therefore, lack substantial evidence of effectiveness due to the fact that there is not a significant patient population requiring the concurrent therapy of an estrogen and an androgen in a fixed dose.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.70 and 5.82), approval of NDA’s 7–661, 8–099, and 9–545 and all amendments and supplements thereto, is hereby withdrawn for the reasons stated above, effective October 29, 1998. Under 21 CFR 314.161 and 314.162(a)(1), four of the estrogen and androgen fixed-dose combination products named above (NDA’s 7–661, 8–099, 9–545, and 11–267) will be removed from the list of drug products with effective approvals published in FDA’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations.” FDA will not approve or accept ANDA’s that refer to these drug products.

Janet Woodcock, Director, Center for Drug Evaluation and Research.

[FR Doc. 98–29049 Filed 10–28–98; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Biological Response Modifiers Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Biological Response Modifiers Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on November 13, 1998, 8 a.m. to 5 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.
Contact Person: Gail M. Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314 or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12389. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will participate in a general scientific discussion of allogeneic transplantation with a focus on haplo-identical transplantation and other high risk transplantations.

Procedure: On November 13, 1998, from 8:30 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person before November 6, 1998. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 9, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On November 13, 1998, from 8 a.m. to 8:30 a.m., the meeting will be closed to the public and open to the company. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 9, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On November 16, 1998, the committee will discuss: (1) New drug application (NDA) 20–886 Panretin® (alitretinoin) Gel 0.1 percent, Ligand Pharmaceuticals Inc., indicated for the first-line topical treatment of cutaneous lesions in patients with acquired immune deficiency syndrome (AIDS)-related Kaposis sarcoma; and (2) NDA 21–041 DepoCyttm (cytarabine liposome injection), DepoTech Corp. indicated for the intrathecal treatment of lymphomatous meningitis.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).


Michael A. Friedman,
Deputy Commissioner for Operations.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Oncologic Drugs Advisory Committee

General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on November 16, 1998, 8:30 a.m. to 5:30 p.m., and on November 17, 1998, 8 a.m. to 5 p.m.

Location: Holiday Inn, Kennedy Grand Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Contact Person: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.

Agenda: On November 16, 1998, the committee will discuss: (1) New drug application (NDA) 20–886 Panretin® (alitretinoin) Gel 0.1 percent, Ligand Pharmaceuticals Inc., indicated for the first-line topical treatment of cutaneous lesions in patients with acquired immune deficiency syndrome (AIDS)-related Kaposis sarcoma; and (2) NDA 21–041 DepoCyttm (cytarabine liposome injection), DepoTech Corp. indicated for the intrathecal treatment of lymphomatous meningitis.

On November 17, 1998, the committee will discuss the labeling of NDA 17–970/S–040 Nolvadex® (tamoxifen citrate), Zeneca Pharmaceuticals, and whether the indication should be “for reducing the short term incidence of breast cancer” in women at high risk of developing the disease or “as a preventative agent for the reduction of breast cancer in women at high risk for developing the disease. The term prevention indicates a reduction in the incidence (risk) of invasive breast cancer over the period of the NSABP P–1 trial, and does not necessarily imply that the initiation of breast cancer has been permanently eliminated.”

Procedure: On November 16, 1998, from 8:30 a.m. to 5:30 p.m., and on November 17, 1998, from 8 a.m. to 1:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 9, 1998. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9 a.m., and between approximately 1:45 p.m. and 2 p.m. on November 16, 1998, and between approximately 8:15 a.m. and 8:45 a.m. on November 17, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 9, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. After the scientific presentations, a 30-minute open public session will be conducted for interested persons who have submitted their request to speak by November 9, 1998, to address issues specific to the submission or topic before the committee.

Closed Committee Deliberations: On November 17, 1998, from 8:30 a.m. to 5 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss personal conflict of interest issues.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).


Michael A. Friedman,
Deputy Commissioner for Operations.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Product and Clinical Development of Tumor Vaccines; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing the following public workshop: Product and Clinical Development of Tumor Vaccines. This workshop, which is cosponsored by FDA and the National Institutes of Health, will assist FDA and the interested public in developing policies and standards for product and clinical development for tumor vaccines.

Date and Time: The public workshop will be held on Thursday, December 10,